INTRODUCTION
Herbal formulation named Valerian or Tagara is widely marketed worldwide mostly for sedative-hypnotic properties. The formulation include the underground organs of members of the genus Valeriana (Valerianaceae), as well as some related genera such as Nardostachys, are used in the traditional medicine of many cultures as mild sedatives and tranquillizers and to aid the induction of sleep. Valerianaoffi cinalis is the species most commonly used in northern Europe and retains its offi cial pharmacopoeial status although it is most commonly encountered as an ingredient of herbal medicines. 1 Indian valerian, Valeriana wallichii is commonly known as Tagara, is anherb recommended by Ayurveda and other ethno medicine streams of India for CNS activities like Sedative-hypnotic and anticonvulsant properties.
Research Guidelines for Evaluating the Safety and Effi cacy of Herbal Medicines
2 published by WHOstates that toxicological evaluation of medicinal plants has been neglected since prolonged and apparently uneventful use usually is considered as anevidence of its safety. However, a history of traditional usage is not always a reliable guarantee of safety since it was never evaluated scientifi cally to detect or monitor delayed effects, rare adverse effects, and adverse effects arising on chronic use of food supplements and nutraceuticals. Further many organizations like WHO and ICMR have expressed the urgent need for validation of indigenous medicines as these could be potential alternative to fi ll in the treatment gap due to lack of suffi cient supply and further may help in the discovery of novel active principles and targets.
The widely used herb tagara consists of predominantly dried rhizome, stolon and small portion of root of Valeriana wallichii DC, (Fam. Caprifoliaeceae): a hairy perennial herb, growing in temperate Himalayas from Kashmir to Bhutan and Khasiahillsup to an altitude of 3,000 m. 3 These plants have been the subject of considerable research, aiming at establishing the pharmacological basis of the activity with both animal and clinical studies. 4 Valeriana wallichii is classifi ed under family Caprifoliaeceae but until recent years Valeriana wallichii was classifi ed under family Valerianaceae. In this work the older classifi cation system is found to be more suitable since the phytopharmacological profi le of the plant is better shared by the members of the family Valereaneceae than of Caprifoliaeceae. 18 Glycine receptors, Adenosine, Nitric oxide signalling pathway, potassium channel opening, 19 Anticholinesterase inhibition, modulation of brain monoamine levels inhibition of prostaglandin synthesis. 20 Chemical constituents identifi ed or isolated from the herb are 6-methylapigenin, acyl-linarin, 21 minor iridoids, 22 4-methoxy-8-pentyl-1-naphthoic acid, 23 methylelcosanoate, acevaltrate, isovaleroxyhydroxydidrovaltrateanddidrovaltrate, 24 podophyllotoxin and pinoresinol, 4'-demethylpodophyllotoxin, β-bisabolol, α-kessyl alcohol, valeranone, bornylisovalerate and linarin-2-O-methylbutyrate. 25 Clinical studies on stress management 26 and sleep quality are published on this herb. 
MATERIALS AND METHODS

Collection, authentication and extraction
Collection
Study design
Acute toxicity study: Acute toxicity was studied in a group of Swiss albino mice(n=6; 3 males and 3 females) by administering 2000 mg/kg body weight of test drug Valeriana wallichii rhizome hydroethanolic extract(VWRHEE) orally as per OECD guidelines. The test method 425 was selected from many acute toxicity test methods available in view of the fact that this method provide an option for conducting a limit test at a single dose (2000 mg/kg or 5000 mg/kg) prior to the main test which helps to reduce the number of animals used if the test material is not mortal at the limit dose. Considering the published work on the test herb and long history of use without any report of toxicity the selection of this method is appropriate.
Chronic toxicity study: Ninety day repeated once daily oral treatment toxicity study with three(200, 600, 1800 mg/kg/body weight/day) different dosegroups (Swiss albino mice, 2-3 months old, 25-30 g n=6; 3 males, 3 females), the fi rst group was control [Vehicle -0.2% Dimethyl sulfoxide], Second group was treated with 200 mg/kg body weight of test drug Valeriana wallichii rhizome hydroethanolic extract (VWRHEE) once daily orally, Third group was treated with 600 mg/kg body weight of VWRHEE once daily, Fourth group was treated with 1800 mg/kg body weight of VWRHEE once daily, with selected in life parameters (physical, behavioural) and post mortem parameters (haematological, biochemical, gross necropsy and histo-pathological) as per Research guidelines for evaluating the safety and effi cacy of herbal medicines by World health organization. Parameters of the study are detailed below 29 of animals or if found dead. Macroscopic examination of organs and tissues and Histo-pathological examinations are to be done only if changes are found on gross or macroscopic examination of their organs and tissues of these animals or if the highest dose group reveal signifi cant changes. Euthanasia: Immediately for Moribund animals and for others at the end of the study (90 days) Ketamine over dose (350 mg/kg/ip).
Ethical approval
The experimental protocol was approved by the Institutional Animal Ethical Committee (IAEC), Yenepoya University and care of laboratory animals was taken as per Committee 
RESULTS
Acute toxicity test
At the single oral limit dose of 2000 mg/kg, in a group of six mice, no signs of abnormality, morbidity or mortality were observed during 14 days of observation.
Chronic toxicity study
Signifi cant differences between the treated and control groups were observed in the following parameters: Loss of Auditory startle (alarm reaction), Aggressiveness (Control > treated), Nasal discharge, Dyspnoea (Figure 2 : Chronic toxicity -Physical examination and behavioural observations). There were 6 deaths during the study, but there was no signifi cant difference in mortality rate between groups. At necropsy, tracheitis was observed in 3 cases. Histo-pathological analysis of liver and kidney samples did not show any sign of toxicity in any of the tested animals.
Results from Photoactometer test indicates dose dependent increase in sedative property without motor incoordination as indicated by all animals passing rota rod test (Figure 3) . VwRHEE was not found to be toxic at the dose ranges during the period of 90 days as per physical examination, behavioural observation, biochemical, haematological (Table 1) , gross necropsy and Histo-pathological reports. The drugs were administered daily for 90 days, the animals were observed daily for any untoward effect, few animals showed loss of auditory startle (alarm reaction), aggressiveness, and nasal discharge. It was also observed that aggressiveness of some animals in the control group. Dyspnoea were also observed in the last two weeks.
DISCUSSION
'Valerian' the herbal formulation of Valeriana wallichii rhizome is one of the most widely used herb all over The present study is a preliminary step towards pharmacological and toxicological profi ling of the herb to aid the rational clinical application. Acute toxicity and 90 day chronic toxicity study is essential but not enough to meet the requirements prior to commencement of human trial. Considering the long term use of the herb in humans a chronic toxicity study of one year duration is the minimum requirement as per WHO guidelines on evaluation of safety of herbal medicines. Further conventional guidelines also suggest toxicity study in multiple species in order to improve predictive power of the effects in humans. Most of the adverse effects observed in the study were mild and the sedative property in compliance with reports on CNS depressant and GABAergic activities of the extract.
Valerianawallcihii rhizome hydro-ethanolic extract is found to be safe with mild adverse effects in few animals; most of whichwasnot dose dependant indicating that the effects may be related to other variables like artefacts or to handling.
From this work it could be concluded that Valerianawallcihii rhizome hydroethanolic extract didn't exhibit mortality, morbidity or any other neurologic, heamatologic, biochemical adverse effectsapart from sedation which is extension of their known pharmacological activity, at 200 mg/kg, 600 mg/kg and 1800 mg/kg oral treatment for 90 days in healthy adult Swiss albino mice. 
CONCLUSION
